A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study to Evaluate Clinical Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants With Alopecia Areata
In the register
The register attaches this trial to Deucravacitinib (Bristol Myers Squibb), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Terminated early
- Declared phase
- Phase 2
- Sponsor
- Bristol-Myers Squibb
- Participants (registry)
- 94
- Start
- November 2022
- Primary completion
- January 2024
- Study completion
- May 2024
- Last registry update
- May 2025
- Countries
- United States, Australia, Canada, France, Japan, Poland
Conditions studied: Alopecia Areata
Interventions: Deucravacitinib, BMS-986165, Placebo
Other trials of Deucravacitinib
Deucravacitinib in the Treatment of Cicatricial Alopecias
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.